Physician profile
Nathan Schramm
NPI 1265682876
$33,841.06
in general payments reported to CMS, 2019-2025
25 companies · $3,499 in 2025
The $3,499 reported for 2025 was more than what 95% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,232 · 2020: $1,500 · 2021: $1,338 · 2022: $2,567 · 2023: $4,936 · 2024: $15K · 2025: $3,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $5,198 · Gift: $4,775 · Entertainment: $85.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,146.95 |
| Consulting Fee | $5,197.50 |
| Gift | $4,775.00 |
| Entertainment | $85.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $7,831.68 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $5,749.94 | 2024-2025 | Xdemvy |
| Visionary Optics LLC | $5,323.25 | 2022-2025 | |
| Visioneering Technologies, INC. | $4,862.24 | 2024 | |
| Bausch & Lomb Americas INC. | $2,422.39 | 2022-2025 | Miebo, Infuse, Xiidra |
| Glaukos Corporation | $1,442.94 | 2022-2025 | Photrexa Viscous and Photrexa, Idosetr, Ce-Marked Kxla System |
| Alcon Vision LLC | $904.89 | 2022-2025 | Tryptyr, Wavelight Refractive Suite |
| Oyster Point Pharma, INC. | $735.84 | 2022-2024 | Tyrvaya |
| Sight Sciences, INC. | $687.87 | 2022-2024 | Tearcare System, Omni Surgical System |
| Harrow Eye, LLC | $592.39 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $576.26 | 2022-2024 | Acuvue |
| Coopervision INC. | $533.93 | 2022-2025 | Myday Contact Lens, Onefit Contact Lens, Misight Contact Lens |
| Astellas Pharma US INC | $383.72 | 2024-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $355.91 | 2024-2025 | Syfovre |
| Lombart Brothers, INC. | $285.57 | 2025 | Opd-III |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $266.17 | 2024 | M22 |
| Dompe US, INC. | $228.34 | 2023-2025 | Oxervate |
| Ocular Therapeutix, INC. | $143.42 | 2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $138.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $122.01 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $99.93 | 2019 | |
| Optos, INC. | $85.01 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Visionix USA, INC | $31.25 | 2022 | |
| Thea Pharma INC. | $23.65 | 2023 | |
| Abbvie INC. | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Schramm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.